135 related articles for article (PubMed ID: 36113608)
1. RF - Intralesional 5-Fluorouracil in the Treatment of Nonmelanoma Skin Cancer.
Gil-Lianes J; Morgado-Carrasco D
Actas Dermosifiliogr; 2023 Mar; 114(3):255-256. PubMed ID: 36113608
[No Abstract] [Full Text] [Related]
2. Treatment of cutaneous neoplasms by intralesional injections of 5-fluorouracil (5-FU).
Kurtis B; Rosen T
J Dermatol Surg Oncol; 1980 Feb; 6(2):122-7. PubMed ID: 7354186
[TBL] [Abstract][Full Text] [Related]
3. RF - Pharmacological Prevention of Nonmelanoma Skin Cancer in High-Risk Patients.
Bosch-Amate X; Morgado-Carrasco D; Martínez N
Actas Dermosifiliogr (Engl Ed); 2020 Sep; 111(7):609-610. PubMed ID: 32531241
[No Abstract] [Full Text] [Related]
4. Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons.
Chitwood K; Etzkorn J; Cohen G
Dermatol Surg; 2013 Sep; 39(9):1306-16. PubMed ID: 23915332
[TBL] [Abstract][Full Text] [Related]
5. [Topical cytostatic treatment of epitheliomas with a 5 per cent 5-fluorouracil ointment].
Ebner H
Z Haut Geschlechtskr; 1968 Sep; 43(18):757-62. PubMed ID: 5715906
[No Abstract] [Full Text] [Related]
6. Intralesional chemotherapy for nonmelanoma skin cancer: a practical review.
Kirby JS; Miller CJ
J Am Acad Dermatol; 2010 Oct; 63(4):689-702. PubMed ID: 20605654
[TBL] [Abstract][Full Text] [Related]
7. Intralesional 5-Fluorouracil for Treatment of Non-Melanoma Skin Cancer: A Systematic Review.
Maghfour J; Kuraitis D; Murina A
J Drugs Dermatol; 2021 Feb; 20(2):192-198. PubMed ID: 33538569
[TBL] [Abstract][Full Text] [Related]
8. 5-fluorouracil (5-FU) ointment in the treatment of benign and malignant skin lesions.
Midana A; Leigheb G
Dermatologica; 1970; 140():Suppl 1:75-81. PubMed ID: 5471366
[No Abstract] [Full Text] [Related]
9. 5-fluouracil (5-FU) ointment in the treatment of skin tumours and keratoses.
Almeida Gonçalves JC; De Noronha T
Dermatologica; 1970; 140():Suppl 1:97+. PubMed ID: 5471370
[No Abstract] [Full Text] [Related]
10. Dilute Intralesional 5-Fluorouracil for the Treatment of Squamous Cell Carcinomas and Keratoacanthomas: A Case Series.
Marka A; Rodgers D; Zelaya Castillo L; Hoyt B; Chapman M; Carter J
J Drugs Dermatol; 2023 May; 22(5):507-508. PubMed ID: 37133471
[TBL] [Abstract][Full Text] [Related]
11. 5-fluorouracil ointment in tumors of the skin.
De Moragas JM; Gimenez-Camarasa JM
Dermatologica; 1970; 140():Suppl 1:65-74. PubMed ID: 5471365
[No Abstract] [Full Text] [Related]
12. Intralesional therapy for the treatment of keratoacanthoma.
Kiss N; Avci P; Bánvölgyi A; Lőrincz K; Szakonyi J; Gyöngyösi N; Fésűs L; Lee G; Wikonkál N
Dermatol Ther; 2019 May; 32(3):e12872. PubMed ID: 30866135
[TBL] [Abstract][Full Text] [Related]
13. Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part II: Photodynamic Therapy, Vismodegib, Cetuximab, Intralesional Methotrexate, and Radiotherapy.
Gracia-Cazaña T; Salazar N; Zamarrón A; Mascaraque M; Lucena SR; Juarranz Á
Actas Dermosifiliogr; 2016 Nov; 107(9):740-750. PubMed ID: 27436804
[TBL] [Abstract][Full Text] [Related]
14. [Topical therapy of precancerous lesions and skin carcinomas using a 5-fluorouracil ointment].
Uthida-Tanaka AM; Nakamura S; de Britto-Costa R; de Tavares Mello E
Hospital (Rio J); 1969 Dec; 76(6):2207-20. PubMed ID: 5309543
[No Abstract] [Full Text] [Related]
15. Intralesional 5-fluorouracil (FU) as a treatment for nonmelanoma skin cancer (NMSC): A review.
Metterle L; Nelson C; Patel N
J Am Acad Dermatol; 2016 Mar; 74(3):552-7. PubMed ID: 26577512
[TBL] [Abstract][Full Text] [Related]
16. Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders.
Moore AY
J Dermatolog Treat; 2009; 20(6):328-35. PubMed ID: 19954388
[TBL] [Abstract][Full Text] [Related]
17. Preliminary studies in the use of 5-fluoro-uracil cream in the treatment of malignant and premalignant skin tumours.
Anderson FE; Johnson AM; Havyatt MT
Med J Aust; 1969 Aug; 2(8):385-8. PubMed ID: 5821141
[No Abstract] [Full Text] [Related]
18. Eruptive squamous atypia (also known as eruptive keratoacanthoma): Definition of the disease entity and successful management via intralesional 5-fluorouracil.
Que SKT; Compton LA; Schmults CD
J Am Acad Dermatol; 2019 Jul; 81(1):111-122. PubMed ID: 31103317
[TBL] [Abstract][Full Text] [Related]
19. A novel therapeutic combination approach for treating multiple vemurafenib-induced keratoacanthomas: systemic acitretin and intralesional fluorouracil.
LaPresto L; Cranmer L; Morrison L; Erickson CP; Curiel-Lewandrowski C
JAMA Dermatol; 2013 Mar; 149(3):279-81. PubMed ID: 23552479
[No Abstract] [Full Text] [Related]
20. Debulking followed by intralesional 5-fluorouracil for the treatment of cutaneous squamous cell carcinoma and keratoacanthoma: A retrospective analysis.
Hamad J; Jolly PS
Dermatol Ther; 2021 Nov; 34(6):e15139. PubMed ID: 34549487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
